Phanes Therapeutics’ spevatamig data puts cold-tumor immunotherapy back in focus at ASCO 2026
See how Phanes Therapeutics’ spevatamig data could reshape metastatic pancreatic cancer drug development after ASCO 2026.
Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study
ALX Oncology has a CD47 signal. The harder test is whether ASPEN-09 can turn a tiny responder cohort into Phase 2 confidence.
What ALX Oncology’s new CD47 findings suggest about biomarker-driven immuno-oncology strategies
Discover how ALX Oncology’s CD47 biomarker data could reshape immuno-oncology strategies and what risks still stand for evorpacept.
Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.